
A Pittsburgh cohort study linked DunedinPACNI brain MRI scores to later blood-based aging composites, with longitudinal replication still needed.

On November 7, 2026, npj Aging published “Longitudinal prediction of biological aging: replication and extension of DunedinPACNI,” a study using two University of Pittsburgh cohorts. The open-access brief communication evaluated DunedinPACNI (Dunedin Pace of Aging Calculated from NeuroImaging), an MRI-derived measure intended to estimate physiological aging from structural brain features.
Faster DunedinPACNI scores were associated with higher blood-based biological-aging composites in both cohorts. In the longitudinal subgroup, faster baseline scores were also associated with higher follow-up composites than expected from baseline blood measurements. The researchers interpreted the findings as support for a brain-based marker associated with aging across physiological systems. For longevity research, the important result is that a measurement derived from the brain was linked to later aging-related measurements elsewhere in the body.
This was an observational study in humans, not an in vitro experiment or an animal-model study.
The paper was an extension of earlier DunedinPACNI work. Its contribution was to test an existing brain-imaging measure against multisystem blood composites and add follow-up in AHAB. This separates the question of how a score is built from the question of whether it relates to measurements collected later.
According to News-Medical's study coverage, the analysis included 451 participants in Adult Health and Behavior (AHAB) and 295 in Neurobiology of Adult Health (NOAH). Together, these independent University of Pittsburgh cohorts provided 746 participants for cross-sectional analyses.
Cross-sectional comparisons examine how measurements relate within the same assessment period. Here, the researchers asked whether people with faster MRI-derived aging scores also had higher multisystem biological-aging composites. Finding an association in both cohorts supplied a replication of that cross-sectional pattern.
That comparison matters because the MRI score and the blood composite represent different kinds of information. The analysis placed a structural brain measure alongside a summary drawn from blood biomarkers. The link between them is the research question, rather than an assumption that they measure exactly the same thing.
The researchers created the blood-based composites from standardized biomarkers. AHAB used eight biomarkers and NOAH used six, selected from a recommended panel of nine. The panel included insulin and IGF-1 along with CRP and IL-6. It also included NT-proBNP and TNF-α as well as GDF15 and cystatin C; HbA1c completed the panel.
The relevant endpoint was the combined biological-aging score. This means the reported association concerns an aggregate of laboratory measurements rather than a separately established finding for every biomarker in the panel. Reading the result at the composite level preserves the distinction between what was analyzed and what a reader might assume about individual tests.
That distinction is useful when comparing the signals behind biological-age measurements. A finding becomes easier to interpret when the reader identifies both sides of the comparison: the proposed marker and the outcome used to evaluate it.
For the longitudinal analysis, 224 AHAB participants had a second blood-biomarker assessment between 7 and 15 years after baseline. News-Medical reports that faster baseline DunedinPACNI was associated with higher follow-up biological-aging composite scores than expected from the participants' baseline measurements.
This asks a different question from the cross-sectional comparison. Instead of looking only at whether scan scores and blood scores were associated at baseline, the analysis tested whether the initial scan score related to a later composite after accounting for the starting measurement. The time order gives the study its longitudinal contribution.
The important phrase is “than expected from baseline measurements.” It places the follow-up result in the context of where participants began. The finding is therefore more specific than a simple association between a scan and a blood sample collected years afterward.
The coverage reports comparisons with three alternative brain-age measures: brainageR and ENIGMA plus DeepBrainNet. The DunedinPACNI association persisted after adjustment for those measures. None of the alternatives independently predicted longitudinal change in the composite in that analysis.
The purpose of this comparison was to ask whether the DunedinPACNI signal remained after accounting for other brain-age estimates. The result strengthens the rationale for examining what information this particular measure captures. It also makes the choice of comparison measures part of the study's interpretation.
News-Medical also reports that fewer years of education were associated with faster DunedinPACNI in both cohorts after adjustment for age and sex. This was an additional association alongside the blood-biomarker analyses, adding a social characteristic to the set of variables related to the MRI-derived score.
The next decisive step is independent longitudinal replication that tests DunedinPACNI against additional aging measures and examines whether its signal adds useful information about meaningful health outcomes.
Deciding whether DunedinPACNI deserves attention as a research marker requires separating its measured associations from the claims attached to aging scores, a distinction AgeAmaze addresses through clear scientific reporting. For adults facing overstated biological-age claims, the publication explains the strength of evidence behind biomarkers so preliminary findings remain in proportion to what researchers have established.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.



Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog